Citation

Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG.: Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem, Volume 56 (18), 2013

Authors

Cap M, Devasthale P, Egan D, Feng J, Fevig J, Fura A, Hamann LG., Harrity T, Kirby MS, Kish K, Klei HE, Levesque P, Li YX, Morgan N, Moulin F, Sun L, Wang A, Wang W, Wang Y, Weigelt C, Zahler R

Journal

J Med Chem

Year

2013

DOI

10.1021/jm4008906

PubMed

23964740

Machine-readable

REST APIRDF